Quantitative Systems Pharmacology: A Case for Disease Models

被引：48
|
作者：
Musante, C. J. [1 ]
Ramanujan, S. [2 ]
Schmidt, B. J. [3 ]
Ghobrial, O. G.
Lu, J. [4 ]
Heatherington, A. C. [1 ]
机构：
[1] Pfizer Inc, Cambridge, MA 02139 USA
[2] Genentech Inc, San Francisco, CA USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] AstraZeneca, Cambridge, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / 01期
关键词：
PHARMACEUTICAL-INDUSTRY; MONOCLONAL-ANTIBODIES; DRUG DEVELOPMENT; THERAPEUTICS; CHALLENGES; INNOVATION; DISCOVERY;
D O I：
10.1002/cpt.528
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model-informed drug discovery and development, supporting program decisions from exploratory research through late-stage clinical trials. In this commentary, we discuss the unique value of disease-scale "platform" QSP models that are amenable to reuse and repurposing to support diverse clinical decisions in ways distinct from other pharmacometrics strategies.
引用
收藏
页码：24 / 27
页数：4
相关论文
共 50 条
  • [31] Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet
    Helmlinger, Gabriel
    Al-Huniti, Nidal
    Aksenov, Sergey
    Peskov, Kirill
    Hallow, Karen M.
    Chu, Lulu
    Boulton, David
    Eriksson, Ulf
    Hamren, Bengt
    Lambert, Craig
    Masson, Eric
    Tomkinson, Helen
    Stanski, Donald
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : S39 - S46
  • [32] Bayesian Quantitative Disease-Drug-Trial Models for Parkinson's Disease to Guide Early Drug Development
    Lee, Joo Yeon
    Gobburu, Jogarao V. S.
    AAPS JOURNAL, 2011, 13 (04): : 508 - 518
  • [33] From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling
    Wang, Hanwen
    Arulraj, Theinmozhi
    Ippolito, Alberto
    Popel, Aleksander S.
    NPJ DIGITAL MEDICINE, 2024, 7 (01):
  • [34] Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations
    Thiel, Christoph
    Smit, Ines
    Baier, Vanessa
    Cordes, Henrik
    Fabry, Brigida
    Blank, Lars Mathias
    Kuepfer, Lars
    NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2018, 4
  • [35] Systems Pharmacology: Defining the Interactions of Drug Combinations
    van Hasselt, J. G. Coen
    Iyengar, Ravi
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59, 2019, 59 : 21 - 40
  • [36] Pharmacometrics and systems pharmacology for metabolic bone diseases
    Riggs, Matthew M.
    Cremers, Serge
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1136 - 1146
  • [37] Pharmacology of Alzheimer's disease:: appraisal and prospects
    Sellal, F
    Nieoullon, A
    Michel, G
    Michel, BF
    Lacomblez, L
    Geerts, H
    Stula, AD
    Bordet, R
    Bentué-Ferrer, D
    Allain, H
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2005, 19 (5-6) : 229 - 245
  • [38] Clinical pharmacology and neuroprotection in Parkinson's disease
    Nomoto, M
    PARKINSONISM & RELATED DISORDERS, 2003, 9 : S55 - S58
  • [39] Toward Quantitative Models in Safety Assessment: A Case Study to Show Impact of Dose-Response Inference on hERG Inhibition Models
    Melnikov, Fjodor
    Anger, Lennart T. T.
    Hasselgren, Catrin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [40] Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework
    Jason H. Williams
    Kai H. Liao
    Donghua Yin
    Xu Meng
    The AAPS Journal, 26
12345